Rayonier Advanced Materials Announces Third Quarter 2021 Results

*Sale of lumber and newsprint assets for approximately $232 million; estimated gain on sale of $6 million, net of tax
*Retired $127 million of senior unsecured debt; additional $25 million of senior secured debt repaid in October
*Expect significant price increases on the majority of cellulose specialties contracts in 2022
*Net loss from continuing operations was $13 million, $26 million unfavorable to the comparable period in 2020, driven by income tax benefit recorded in the prior year
*Adjusted EBITDA from continuing operations was $35 million, up $3 million from the comparable quarter in 2020, driven by higher High Purity Cellulose and High-Yield Pulp prices offset by impacts of cost inflation
*Targeting EBITDA margin growth focused on lowering cost, improving reliability, executing strategic projects and funding attractive innovation initiatives

Rayonier Advanced Materials Inc. (NYSE:RYAM) (the “Company”) reported a net loss of $5 million or a net loss of $0.07 per diluted share, compared to net income of $29 million or $0.45 per diluted share for the same prior year quarter. The net loss from continuing operations for the quarter ended September 25, 2021 was $13 million or $0.21 per diluted share, compared to net income from continuing operations of $13 million or $0.20 per diluted share for the same prior year quarter. The decrease in the diluted earnings per share was primarily due to significant income tax benefits recorded in the prior year. Income from discontinued operations for the quarter ended September 25, 2021 was $9 million or $0.14 per diluted share, compared to income from discontinued operations of $16 million or $0.25 per diluted share for the same prior year quarter. The decrease in the diluted earnings per share was due to lower lumber sales volumes as only two months of activity are recorded in the current quarter along with a higher income tax expense. As a result of the sale of lumber and newsprint assets, the Company has reclassified certain prior year amounts to conform to the current year presentation for discontinued operations. Unless otherwise stated, information in this press release relates to continuing operations.

“We made great progress on our strategic initiatives in the quarter including completion of the portfolio optimization initiative,” said Paul Boynton, President and Chief Executive Officer. “Along with our sale of the lumber and newsprint assets, we repaid a significant amount of debt and built cash reserves, which will be used to make investments in lowering cost, improving reliability and growing our BioFuture over the coming years. As we experience significant cost inflation and strong demand for cellulose specialties products, which are expected to continue into 2022, it is imperative that we capture fair value for our products to maintain our capital-intensive assets and service our customers. As such, we expect significant price increases on our majority of cellulose specialties contracts in 2022.”
details at: https://investors.rayonieram.com/news-releases/news-release-details/rayonier-advanced-materials-announces-third-quarter-2021-results

Related Posts

The sale of a 30 percent stake in the Husum pulp mill to Norra Skog has been completed

Metsä Board, part of Metsä Group, announced on 1 December 2020 that it had signed an agreement to sell a 30 percent stake in its Husum pulp mill in Sweden to the Swedish forest owners' cooperative Norra Skog. The transaction was completed on 4 January 2021, and its impacts will be included in Metsä Board's financial reporting as of the January–March 2021 interim report.

UPM Biomedicals and CELLINK form collaboration for groundbreaking 3D bioprinting developments

UPM Biomedicals is excited to announce its collaboration with bioconvergence company CELLINK. The partnership brings together UPM’s expertise for producing non-animal derived, nanocellulose biomaterials with CELLINK’s years of experience in method development for 3D bioprinting, offering new groundbreaking solutions to this growing life sciences market. Advances in 3D printing in the past decade have been outstanding, and the technology is becoming more widely used for various cutting-edge applications. 3D bioprinting is already important in areas such as cancer research, where tumour models can be printed to test their response to different treatments. More recently scientists have been exploring the use of this technology in a clinical setting, with the possibility of printing tissues or organs that can then be transplanted into patients. Using non-animal derived raw materials, such as UPM’s nanofibrillar cellulose, for bio-ink formulations makes transplants into humans much more effective, reducing the possibility of an immune response or rejection.
Back To Top
×Close search
Search